Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 15, 2025 11:24 ET | Source: HMNC Holding GmbH

Ketabon Presents New Data Showing Antidepressant Effects of Oral Ketamine (KET01) Are Independent of Dissociation

Ketabon, a JV between HMNC and Develco, shared new post hoc Phase 2 data for oral ketamine (KET01) in treatment-resistant depression (TRD)
October 13, 2025 08:00 ET | Source: HMNC Holding GmbH

HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam

HMNC presented data showing distinct nelivaptan response patterns, supporting its precision, genetics-guided approach to treating depression.